ReviewInflammopharmacology2023
What is really 'Long COVID'?
Review in Inflammopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Risk of long covid in patients with pre-existing chronic respiratory diseases: a systematic review and meta-analysis.BMJ open respiratory research · 2025Pooled it
- Evaluation of vascular photobiomodulation for orofacial pain and tension type headache following COVID 19 in a pragmatic randomized clinical trial.Scientific reports · 2024Trial
- Proteomic and Phosphoproteomic Characteristics of Multiple Brain Regions in Rhesus Macaques After SARS-CoV-2 Infection.MedComm · 2026Article
- Effect of Long COVID-19: Self-Reported Questionnaires and Objective Olfactory and Gustatory Evaluations.Diseases (Basel, Switzerland) · 2026Article
- Persistent Neurological Symptoms in Chronic Disease Patients After COVID-19 Infection in Jamaica: A Retrospective Cohort Study Exploring Clinical Manifestations of Long COVID in a Low and Middle Income Country.Health science reports · 2026Article
- Long COVID: a review of mechanisms and treatment modalities.Inflammopharmacology · 2026Review
- Article
- The hidden burden: prevalence and risk factors of long COVID among university students in Chiang Mai, Thailand.BMC public health · 2025Article
- Unveiling the secret of cellular metamorphosis: the crucial role of EndMT mechanisms in COVID-19-induced pulmonary fibrosis.Inflammopharmacology · 2025Review
- Determinants of work ability among health and social services workers with work-related COVID-19 infection in Germany.BMC health services research · 2025Article
- Postacute Sequelae From SARS-CoV-2 at the University of Illinois Hospital and Clinics: An Examination of the Effects of Long COVID in an Underserved Population Utilizing Manual Extraction of Electronic Health Records.American journal of medicine open · 2025Article
- Long COVID's Hidden Complexity: Machine Learning Reveals Why Personalized Care Remains Essential.Journal of clinical medicine · 2025Article
- Long COVID has variable incidence and clinical presentations: our 6-country collaborative study.Inflammopharmacology · 2025Article
- Chronic inflammation in post-acute sequelae of COVID-19 modulates gut microbiome: a review of literature on COVID-19 sequelae and gut dysbiosis.Molecular medicine (Cambridge, Mass.) · 2025Review
- The healthcare burden imposed by children with gastroparesis and the shift imposed by COVID-19.Frontiers in pediatrics · 2025Article
- Food and medicine homology: a potential nutritional intervention strategy for post-acute COVID-19 syndrome.Frontiers in pharmacology · 2025Review
- The risk factors for long term cardiovascular symptoms in patients after coronavirus disease 2019 infection.Annals of medicine · 2024Observational
- Comparison of Metabolic Syndrome, Autoimmune and Viral Distinctive Inflammatory Related Conditions as Affected by Body Mass Index.Journal of clinical medicine · 2024Article
- Persistence of COVID-19 Symptoms and Quality of Life at Three and Twelve Months after Hospital Discharge.Medicina (Kaunas, Lithuania) · 2024Observational
- COVID-19 and persistent symptoms: implications for polycystic ovary syndrome and its management.Frontiers in endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The previous acute respiratory diseases caused by viruses originating from China or the middle east (e.g., SARS, MERS) remained fast developing short diseases without major sequalae or any long-lasting complications. The new COVID-19, on the other hand, not only that it rapidly spread over the world, but some patients never fully recovered or even if they did, a few weeks later started to complain not only of shortness of breath, if any, but general weakness, muscle pains and 'brain fog', i.e., fuzzy memories. Thus, these signs and symptoms were eventually labelled 'long COVID', for which the most widely used definition is 'new signs and symptoms occurring 4-8 weeks after recovering from acute stage of COVID-19'. The other most frequent manifestations associated with long COVID include headache, loss of memory, smell and of hair, nausea, and vomiting. Thus, long COVID is not a simple disease, but complex disorder of several organ systems malfunctioning; hence, it is probably more appropriate to call this a syndrome. The pathogenesis of long COVID syndrome is poorly understood, but initial and persistent vascular endothelial injury that often triggers the formation of microthrombi that if dislodged as emboli, damage several organs, especially in the brain, heart and kidney, by creating microinfarcts. The other major contributory mechanistic factor is the persistent cytokine storm that may last longer in long COVID patients than in others, probably triggered by aggregates of SARS-Co-2 discovered recently in the adrenal cortex, kidney and brain. The prevalence of long COVID is relatively high, e.g., initially varied 3-30%, and recent data indicate that 2.5% of UK population suffers from this syndrome, while in the US 14.7% of acute COVID-19 patients continued to have symptoms longer than 2 months. Thus, the long COVID syndrome deserves to be further investigated, both from clinical and basic research perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.